Philip Morris International has seen moderate performance with a focus on innovation in the smoke-free product sector. The shift towards a smoke-free portfolio aligns with growing health consciousness. However, competition and regulatory challenges in the tobacco industry continue to pose risks.
The overall rating for Philip Morris is currently a C+ which suggests potential but with areas of concern.
| Category | Score | Score Bar |
|---|---|---|
| Discounted Cash Flow | 3 | |
| Return on Equity | 1 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 1 |
There has been little fluctuation in the historical ratings over the assessed period, indicating stability in performance.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-02-05 | 2 | 3 | 1 | 5 | 1 | 2 | 1 |
| Previous | 0 | 3 | 1 | 5 | 1 | 2 | 1 |
Analysts provide a favorable outlook with a consensus of 'Buy'.
| High | Low | Median | Consensus |
|---|---|---|---|
| $180 | $175 | $180 | $178.33 |
The stock has garnered significant 'Buy' ratings, with limited interest in 'Sell'.
| Recommendation | Count | Sentiment Bar |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 17 | |
| Hold | 7 | |
| Sell | 1 | |
| Strong Sell | 0 |
Philip Morris International Inc. shows potential with its strategic pivot towards smoke-free products, aligning with global health trends. While the stock is currently rated as a 'Buy' by analysts, challenges arising from regulatory changes and market competition remain. The company's financial health exhibits strengths in Return on Assets, though debt levels and profitability ratios are concerns. Overall, PM presents a stable investment opportunity with room for growth as it transitions its product offerings.